What does the ExoDx prostate cancer test measure?
The ExosomeDx test is a urine test that measures and analyzes exosomal RNA for three biomarkers present in men with high-grade prostate cancer: ERG, PCA3 and SPDEF.
The ExosomeDx test, commonly called the ExoDx test, is used in addition to the PSA test and other standard of care data points (including age, race, and family history) to help healthcare providers determine if an initial biopsy is necessary or if the patient can continue to be monitored. The ExoDx test specifically helps determine if a patient may not have high grade prostate cancer.
Learn more about the ExosomeDx test, which assesses a patient’s individual risk for high-grade prostate cancer and whether or not a biopsy may be necessary.
Understanding Your ExoDx Results
ExoDx Prostate can be an effective test for using in combination with the PSA and other personal health factors to predict if a patient should be referred for an initial prostate biopsy. See a sample ExoDx results report and learn more about how to interpret the report. Please not that all test results like those of ExoDx should be reviewed with a healthcare provider.
Below is an initial list of frequently asked questions about the ExosomeDx test. You can also submit your question.
The PSA test cannot differentiate between prostate cancer and non-cancerous (benign) conditions, such as benign prostatic hyperplasia (BPH). Men who receive a PSA level above 1.5 ng/ML should discuss additional biomarker testing with their healthcare providers prior to considering a prostate biopsy.
Prostate cancer biomarkers (PCMs) are molecules found in blood, tissue, or body fluids. PCMs are revolutionary new, non-invasive diagnostic tests that may help your healthcare provider decide if your prostate cancer is in fact low risk, if something more aggressive may be lurking in your prostate, or if there are hot spots in the prostate that may need to be re-evaluated upon biopsy. PCMs also can help you and your healthcare provider determine the most appropriate treatment for your cancer.
There are many factors that will make one prostate cancer marker test better suited for individual cases. Many times, individuals who have never had a biopsy or had low to intermediate grade prostate cancer (Gleason 3+3=6 or 3+4=7) diagnosed on a biopsy are well suited for blood or urine prostate cancer markers, whereas individuals who have persistently negative biopsies or a biopsy of intermediate to high grade cancer may benefit from tissue prostate cancer markers. Use this interactive questionnaire to see what tests may be right for you. Once you’ve completed the questionnaire, discuss the results with your healthcare provider. Also be sure to check out our Patient Journey section that may help you decide which test is right for you.
Although there are many factors that contribute to your healthcare provider’s decision to conduct a prostate biopsy, there are several urinary and blood based PCMs that may help guide you and your physician through the decision of conducting a prostate biopsy. These include:
Genetic tests also may be worth considering if you have a family history of prostate cancer, breast cancer, ovarian cancer or colorectal cancer. These genetic tests are recommended for men who are determined through genetic counseling to be at potential risk for hereditary cancer:
Men 50 and older, men with a low risk (Gleason 3+3=6) prostate biopsy, and men with a previously negative prostate biopsy may benefit from the non-invasive, urine-based ExoDx test.
The ExoDx test analyzes exosomal RNA from a non-invasive urine sample for three biomarkers known to be expressed in men with high-grade prostate cancer: ERG, PCA3 and SPDEF. You should consult your physician or healthcare provider when reviewing the results of your ExoDx test.
The ExoDx Score is returned as above or below 15.6, which is the test’s cutoff for high grade prostate cancer.
- If below 15.6, there is a decreased likelihood of greater than or equal to Gleason 7 prostate cancer on biopsy.
- If above 15.6, there is an increased likelihood of greater than or equal to Gleason 7 prostate cancer on biopsy.
See a sample ExoDx test result report and learn more about how to interpret these scores.
Explore more information about the ExosomeDx test.
- ExoDx Patient website
- ExoDx Physician website
- ExoDx At-Home Collection Kit
- ExoDx Prostate Test for Risk Assessment of high-grade prostate cancer (HGPCa) Webinar
- A Novel Urine Exosome Gene Expression Assay to Predict High-Grade Prostate Cancer at Initial Biopsy
- A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-speciﬁc Antigen 2–10 ng/ml at Initial Biopsy